Contents
On the OB-GYN shelf, a prenatal genetics question gives a gestational age and a result (a cell-free DNA report, a nuchal translucency measurement or a quad screen pattern) and asks for the next best step. It tests two things: which test is available at that week, and whether the result in hand is a screen or a diagnosis.
The screening timeline
ACOG recommends offering every pregnant patient both aneuploidy screening and diagnostic testing, whatever her age or risk. Testing is a choice, and declining all of it is also acceptable.
- From 10 weeks: cell-free DNAA maternal blood test that analyzes placental DNA fragments. It is the most sensitive and specific screen for trisomies 21, 18 and 13, and can be drawn any time after 10 weeks. It is still a screen.
- 10 to 13 weeks: chorionic villus samplingDiagnostic. Placental tissue is sampled transcervically or transabdominally. It gives the earliest definitive answer.
- 10 to 13 6/7 weeks: first-trimester combined screenNuchal translucency on ultrasound plus serum PAPP-A and hCG. Trisomy 21 pattern: thick NT, low PAPP-A, high hCG.
- 15 to 22 6/7 weeks: quad screenSerum AFP, hCG, estriol and inhibin A. Trisomy 21 pattern: low AFP, high hCG, low estriol, high inhibin A. Trisomy 18: AFP, hCG and estriol all low.
- From 15 weeks: amniocentesisDiagnostic. Amniocytes are cultured for karyotype or chromosomal microarray. Amniotic fluid AFP and acetylcholinesterase confirm an open neural tube defect.
- 15 to 22 weeks: maternal serum AFPScreens for open neural tube defects. Offer it (or rely on the anatomy scan) even when cfDNA was the aneuploidy screen, because cfDNA does not screen for neural tube defects.
- 18 to 22 weeks: anatomy ultrasoundThe detailed fetal survey. Structural anomalies found here, or an earlier NT of 3.0 mm or more, raise the risk of aneuploidy and change the next step.
Screen or diagnosis: the line the exam draws
| Test | Type | Window | What it can tell you |
|---|---|---|---|
| Cell-free DNA | Screen | 10 weeks onward | Risk of trisomy 21, 18, 13 and sex chromosome aneuploidy; no information on neural tube defects |
| First-trimester combined screen | Screen | 10 to 13 6/7 weeks | Risk of trisomy 21 and 18; a thick NT also flags cardiac defects |
| Quad screen | Screen | 15 to 22 6/7 weeks | Risk of trisomy 21 and 18, plus neural tube defect risk from the AFP |
| Chorionic villus sampling | Diagnostic | 10 to 13 weeks | Fetal karyotype or microarray; cannot measure amniotic fluid AFP |
| Amniocentesis | Diagnostic | 15 weeks onward | Karyotype or microarray, plus amniotic fluid AFP and acetylcholinesterase |
A positive screen is never treated as a diagnosis. No irreversible decision, including termination, rests on a cfDNA, combined or quad screen result alone.
The algorithm after an abnormal result
- Confirm what kind of result it isA screen gives a risk. Only CVS or amniocentesis gives a fetal diagnosis.
- Offer genetic counselingExplain the positive predictive value, which depends on the prior risk: a positive cfDNA in a 25-year-old is less likely to be a true positive than the same result in a 40-year-old.
- Offer a diagnostic test by gestational ageCVS at 10 to 13 weeks, or amniocentesis from 15 weeks. Do not repeat the screen or add a second screen to settle the question.
- Elevated maternal serum AFP: ultrasound firstWrong dates, multiple gestation and fetal demise raise AFP too. Ultrasound confirms dating and looks for an open neural tube or abdominal wall defect before amniocentesis.
- NT of 3.0 mm or more: three referralsOffer diagnostic testing, a detailed anatomy ultrasound and fetal echocardiography, even if the aneuploidy screen comes back low risk.
- Anomaly on ultrasound: order chromosomal microarrayWhen a structural anomaly is seen, microarray on the diagnostic sample is preferred over a karyotype because it detects smaller deletions and duplications.
Clue in the stem, next best step
| Clue in the stem | What it points to | Next best step |
|---|---|---|
| 11 weeks, cfDNA high risk for trisomy 21 | Positive screen | Genetic counseling and CVS (or amniocentesis from 15 weeks) |
| cfDNA returns "no call" | Failed screen, linked to higher aneuploidy risk | Counseling, detailed ultrasound and an offer of diagnostic testing; do not simply reassure |
| 17 weeks, MSAFP 3.1 MoM | Elevated AFP | Ultrasound to confirm dates and look for defects |
| Quad screen: low AFP, high hCG, low estriol, high inhibin A | Trisomy 21 pattern | Counseling and amniocentesis |
| Quad screen: AFP, hCG and estriol all low | Trisomy 18 pattern | Counseling and amniocentesis |
| 12 weeks, NT 3.5 mm | Thick nuchal translucency | Diagnostic testing, detailed anatomy scan, fetal echocardiography |
| 9 weeks, patient wants a diagnostic test now | Too early for CVS | Wait until 10 weeks; CVS before 10 weeks is linked to limb reduction defects |
| CVS result shows mosaicism | Possible confined placental mosaicism | Amniocentesis to test the fetus |
Where students lose points
- Treating cfDNA as diagnostic. It is the best screen, not a diagnosis, and its positive predictive value falls in low-risk patients.
- Ordering amniocentesis for an elevated MSAFP before an ultrasound. Dating error is the most common cause of an abnormal AFP.
- Choosing amniocentesis at 12 weeks. Amniocentesis before 15 weeks carries higher loss rates and a risk of talipes; CVS is the first-trimester diagnostic test.
- Assuming a normal cfDNA rules out a neural tube defect. It does not; that is the job of MSAFP or the anatomy scan.
- Running two aneuploidy screens at the same time. Parallel screening raises false positives without improving detection.
- Limiting the offer of diagnostic testing to patients 35 and older. Every patient is offered both screening and diagnostic testing.
Practice question
A 29-year-old woman, gravida 1, para 0, at 11 weeks of gestation comes for a follow-up visit. Her pregnancy has been uncomplicated, and dating was confirmed by a crown-rump length at 8 weeks. She chose cell-free DNA screening at her first visit; the report shows a high risk for trisomy 21. She is distressed and says she would consider ending the pregnancy if the fetus has Down syndrome. Vital signs are normal. Ultrasound today shows a single live intrauterine fetus with a crown-rump length consistent with 11 weeks.
Which of the following is the most appropriate next step in management?
- Repeat cell-free DNA screening in 2 weeks
- Quad screen at 16 weeks
- Genetic counseling and chorionic villus sampling
- Counseling about termination based on the cfDNA result
- Reassurance, because she is younger than 35
Show the answer
Answer: C. A high-risk cfDNA result is a positive screen. It needs confirmation with a diagnostic test before any irreversible decision. At 11 weeks, CVS is available now and gives a fetal karyotype or microarray; amniocentesis from 15 weeks is the alternative if she prefers to wait.
Why the others are wrong. A and B: repeating the screen or adding a second screen cannot confirm or exclude the diagnosis. D: decisions about the pregnancy should not rest on a screening result, which can be a false positive, especially at lower prior risk. E: age does not make a positive result reassuring, and every patient is offered diagnostic testing.
60-second recall
Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.
1Earliest aneuploidy screen
cfDNA, from 10 weeks.Did you get it?2First-trimester combined screen
NT plus PAPP-A and hCG, 10 to 13 6/7 weeks.Did you get it?3Quad screen in trisomy 21
AFP low, hCG high, estriol low, inhibin A high.Did you get it?4Diagnostic windows
CVS 10 to 13 weeks; amniocentesis from 15 weeks.Did you get it?5Elevated MSAFP
Ultrasound first, to check dates and look for defects.Did you get it?6NT 3.0 mm or more
Diagnostic testing, detailed anatomy scan and fetal echocardiography.Did you get it?
Make retrieval a habit on every topic with Learning to Learn Medicine. Module 1 is free; the full bundle (the course plus all 12 Recall Labs) is a one-time $199.
Next: browse every Board Review post, review the first-trimester bleeding algorithm, or see MedRise for students.
Sources
- American College of Obstetricians and Gynecologists. Screening for fetal chromosomal abnormalities. Practice Bulletin No. 226. Obstet Gynecol, 2020 (PubMed 32804883)
- American College of Obstetricians and Gynecologists. Prenatal diagnostic testing for genetic disorders. Practice Bulletin No. 162. Obstet Gynecol, 2016 (PubMed 26938573)
- LeFevre NM, Sundermeyer RL. Fetal aneuploidy: screening and diagnostic testing. Am Fam Physician, 2020;101(8):481-488
MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.



